Results 261 to 270 of about 42,293 (332)

Safety and Efficacy of Anticoagulation Therapy in Paediatric Patients With Solid Tumours or Lymphomas at Risk of Thrombocytopenia: A Retrospective Study

open access: yesPediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT Background Patients with solid tumours or lymphomas have an increased risk of thromboembolism (TE) and thrombocytopenia. Evidence‐based strategies for anticoagulation therapy (ACT) for patients with thrombocytopenia are limited. We examined the impact of thrombocytopenia on ACT administration and bleeding incidence in children with solid ...
Andrés Felipe Fajardo   +5 more
wiley   +1 more source

Preoperative Cytopenia in Patients Affected by High‐Risk Neuroblastoma: Just a Matter of Platelets?

open access: yesPediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT Background and Aims In patients affected by high‐risk neuroblastoma (HR‐NB), complete macroscopic resection (CMR) is associated with better outcomes. These patients are often cytopenic due to intensive induction regimens. The aim of the present study is to assess the impact of preoperative cytopenia on surgical outcome in patients with HR‐NB ...
Giorgio Persano   +13 more
wiley   +1 more source

Massive transfusion policy in the Netherlands, a nationwide survey. [PDF]

open access: yesTransfusion
Van der Heiden AM   +6 more
europepmc   +1 more source

DNA Methylation Episignature as a Novel Diagnostic Tool for Diamond‐Blackfan Anemia Syndrome

open access: yesAmerican Journal of Hematology, Volume 101, Issue 2, Page 228-241, February 2026.
Diamond‐Blackfan Anemia Syndrome (DBAS) is a congenital bone marrow failure disorder characterized by defective erythropoiesis and a spectrum of congenital anomalies, including craniofacial malformations, limb abnormalities, and cardiac and renal defects.
Paola Quarello   +29 more
wiley   +1 more source

Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial

open access: yesAmerican Journal of Hematology, Volume 101, Issue 2, Page 242-254, February 2026.
ABSTRACT Iptacopan is a first‐in‐class, oral, selective inhibitor of complement factor B that has demonstrated positive efficacy across several complement‐driven diseases. Here we evaluate the efficacy and safety of iptacopan monotherapy in adult patients with primary immune thrombocytopenia (ITP) and primary cold agglutinin disease (CAD). We performed
Alexander Röth   +13 more
wiley   +1 more source

[Reverse apheresis--semiautomatic erythrocyte transfusion].

open access: yesTidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2002
openaire   +1 more source

Home - About - Disclaimer - Privacy